Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides
- PMID: 11458048
Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides
Abstract
Purpose: We investigated antisense inhibition of anti-apoptotic bcl-xL and bcl-2 proteins to increase chemosensitization in the T24 and 5637 bladder carcinoma cell lines.
Materials and methods: A T24 bladder carcinoma cell line stably over expressing bcl-xL protein was constructed. Apoptosis by cytotoxic agents was estimated by cell cycle analysis and Annexin V binding. To eliminate bcl-xL expression T24 and 5637 cells were treated with C5-propynylated and 2'-O-methylribo-oligonucleotides. Levels of protein and messenger RNA were measured by Western and Northern blot analysis. Cell viability after combined treatment with oligonucleotides and various cytotoxic agents was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and evaluated statistically by Student's 2-sample t test.
Results: Forced over expression of bcl-xL protein desensitized the T24 bladder carcinoma cell line to cytotoxic agents. C5-propynylated and 2'-O-methylribo-oligonucleotides down-regulated bcl-xL protein expression in the T24 and 5637 cell lines, and increased their sensitivity to cytotoxic agents. The efficiency of antisense down-regulation of bcl-xL protein expression depended on the type of delivery agent.
Conclusions: Antisense down-regulation of bcl-xL protein sensitizes bladder carcinoma cells to cytotoxic agents. However, it is possible that cellular chemosensitization results from a combination of effects, including nonsequence specificity, irrelevant cleavage and effects of the carriers combined with the specific antisense effects.
Similar articles
-
Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.Cancer Res. 2000 Nov 1;60(21):6052-60. Cancer Res. 2000. PMID: 11085527
-
Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.J Urol. 2009 Mar;181(3):1361-71. doi: 10.1016/j.juro.2008.10.148. Epub 2009 Jan 20. J Urol. 2009. PMID: 19157446
-
The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.J Urol. 2001 Sep;166(3):1098-105. J Urol. 2001. PMID: 11490306
-
[Suppression of expression of bcl-2 and bcl-xL genes using antisense oligonucleotides: a new approach to cancer therapy].Mol Biol (Mosk). 2000 Nov-Dec;34(6):1025-38. Mol Biol (Mosk). 2000. PMID: 11186002 Review. Russian. No abstract available.
-
Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy.Biochim Biophys Acta. 2004 Dec 10;1705(1):43-51. doi: 10.1016/j.bbcan.2004.09.004. Biochim Biophys Acta. 2004. PMID: 15585172 Review.
Cited by
-
In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.J Cancer Res Clin Oncol. 2009 May;135(5):679-86. doi: 10.1007/s00432-008-0500-5. Epub 2008 Oct 22. J Cancer Res Clin Oncol. 2009. PMID: 18941779 Free PMC article. Clinical Trial.
-
Antisense oligonucleotide therapy for urologic tumors.Curr Urol Rep. 2003 Feb;4(1):60-9. doi: 10.1007/s11934-003-0059-2. Curr Urol Rep. 2003. PMID: 12537941 Review.
-
Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma.Br J Cancer. 2013 Jun 11;108(11):2312-20. doi: 10.1038/bjc.2013.216. Epub 2013 May 14. Br J Cancer. 2013. PMID: 23674090 Free PMC article.
-
The role of stress proteins in prostate cancer.Curr Genomics. 2007 Jun;8(4):252-61. doi: 10.2174/138920207781386951. Curr Genomics. 2007. PMID: 18645594 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous